Inhibition of RELM-β Prevents Hypoxia-Induced Overproliferation of Human Pulmonary Artery Smooth Muscle Cells by Reversing PLC-mediated KCNK3 Decline.

Linlin Han,Nannan Song,Xiaomin Hu,Afang Zhu,Xin Wei,Jinmin Liu,Shiying Yuan,Weike Mao,Xiangdong Chen
DOI: https://doi.org/10.1016/j.lfs.2020.117419
IF: 6.78
2020-01-01
Life Sciences
Abstract:Aims: Although resistin-like molecule beta (RELM-beta) is involved in the pathological processes of various lung diseases, such as pulmonary inflammation, asthma and fibrosis, its potential roles in hypoxic pulmonary arterial hypertension (PAH) remain largely unknown. The study aims to investigate whether RELM-beta contributes to hypoxia-induced excessive proliferation of human pulmonary artery smooth muscle cells (PASMCs) and to explore the potential mechanisms of this process. Main methods: Human PASMCs were exposed to normoxia or hypoxia (1% O-2) for 24 h. siRNA targeting RELM-beta was transfected into cells. Protein levels of KCNK3, RELM-beta, pSTAT3 and STAT3 were determined by immunoblotting. The translocation of NFATc2 and expression of KCNK3 were visualized by immunofluorescence. 5-ethynyl-2'-deoxyuridine assays and cell counting kit-8 assays were performed to assess the proliferation of PASMCs. Key findings: (1) Chronic hypoxia significantly decreased KCNK3 protein levels while upregulating RELM-beta protein levels in human PASMCs, which was accompanied by excessive proliferation of cells. (2) RELM-beta could promote human PASMCs proliferation and activate the STAT3/NFAT axis by downregulating KCNK3 protein under normoxia. (3) Inhibition of RELM-beta expression effectively prevented KCNK3-mediated cell proliferation under hypoxia. (4) Phospholipase C (PLC) inhibitor U-73122 could not only prevent the hypoxia/RELM-beta-induced decrease in KCNK3 protein, but also inhibit the enhanced cell viability caused by hypoxia/RELM-beta. (5) Both hypoxia and RELM-beta could downregulate membrane KCNK3 protein levels by enhancing endocytosis. Significance: RELM-beta activation is responsible for hypoxia-induced excessive proliferation of human PASMCs. Interfering with RELM-beta may alleviate the progression of hypoxic PAH by upregulating PLC-dependent KCNK3 expression.
What problem does this paper attempt to address?